Evidence map›Paper›PMID 35131909›Full record

ArticleNeurology2022

Biological and Social Determinants of Hypertension Severity Before vs After Intracerebral Hemorrhage.

Jessica R Abramson, Juan Pablo Castello, Sophia Keins, Christina Kourkoulis, Axana Rodriguez-Torres, Evangelos Pavlos Myserlis, Haitham Alabsi, Andrew D Warren, Jonathan Q A Henry, M Edip Gurol and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Jessica R AbramsonFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Juan Pablo CastelloFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Sophia KeinsFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Christina KourkoulisFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Axana Rodriguez-TorresFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Evangelos Pavlos MyserlisFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Haitham AlabsiFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Andrew D WarrenFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Jonathan Q A HenryFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
M Edip GurolFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Anand ViswanathanFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Steven M GreenbergFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Amytis TowfighiFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Lesli SkolarusFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Christopher D AndersonFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Jonathan RosandFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA.
Alessandro BiffiFrom the Henry and Allison McCance Center for Brain Health (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., J.Q.A.H., C.D.A., J.R., A.B.), Department of Neurology (J.R.A., J.P.C., S.K., C.K., E.P.M., H.A., A.D.W., J.Q.A.H., M.E.G., A.V., S.M.G., C.D.A., J.R., A.B.), and Center for Genomic Medicine (J.R.A., S.K., C.K., E.P.M., J.Q.A.H., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston; School of Medicine (A.R.-T.), University of California, Irvine; Department of Neurology (A.T.), Keck School of Medicine, University of Southern California, Los Angeles; Los Angeles County Department of Health Services (A.T.), CA; Stroke Program (L.S.), University of Michigan Medical School, Ann Arbor; and Department of Neurology (C.D.A.), Brigham and Women's Hospital, Boston, MA. abiffi@mgh.harvard.edu.
Anna Needs Neuroblastoma Answers · US

Funding

Center for Common Disease GeneticsUM1HG008895 · NHGRI · BROAD INSTITUTE, INC. · PI DALY, MARK JOSEPH, GABRIEL, STACEY · 2016 to 2020
$111.2M
Ethnic/Racial Variation in Intracerebral Hemorrhage (ERICH)U01NS069763 · NINDS · UNIVERSITY OF CINCINNATI · PI ANDERSON, CHRISTOPHER DAVID, DEMEL, STACIE · 2010 to 2024
$34.2M
Genetic&Environment Risk Factors for Hemorrhagic StrokeR01NS036695 · NINDS · UNIVERSITY OF CINCINNATI · PI WOO, DANIEL · 1997 to 2012
$14.1M
Recurrent Hemorrhagic Stroke in Minority PopulationsR01NS093870 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI JONATHAN ROSAND, Amytis Towfighi · 2016 to 2026
$12.3M
Sequencing Annotation and Functional Analysis in Risk of Intracerebral HemorrhageR01NS103924 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDERSON, CHRISTOPHER DAVID · 2018 to 2022
$3.4M
Reach Out: Randomized Clinical Trial of Emergency Department-Initiated Hypertension Behavioral Intervention Connecting Multiple Health SystemsR01MD011516 · NIMHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MEURER, WILLIAM JOSEPH, SKOLARUS, LESLI ELIZABETH · 2017 to 2020
$3.3M
Understanding Implications of End-of-life Preferences to Optimize Advance Care Planning Among Older AmericansR01AG059733 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BURKE, JAMES FRANCIS, SKOLARUS, LESLI ELIZABETH · 2018 to 2022
$3.1M
A Community Based Participatory Trial to Increase Stroke TreatmentU01MD010579 · NIMHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROWN, DEVIN L · 2016 to 2020
$2.8M
Platform for Accelerating Genetic Discovery for Cerebrovascular DiseaseR24NS092983 · NINDS · BROAD INSTITUTE, INC. · PI ROSAND, JONATHAN · 2015 to 2018
$1.2M
Apathy and Depression following Intracerebral HemorrhageK23NS100816 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI BIFFI, ALESSANDRO · 2017 to 2021
$1.0M
Aging in Place: A Cross-Sector Partnership of Housing and Health CareR21AG071796 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SKOLARUS, LESLI ELIZABETH · 2021 to 2023
$429k
NHGRI NIH HHS UM1 HG008895NIA NIH HHS R01 AG059733NIA NIH HHS R21 AG071796NIMHD NIH HHS R01 MD011516NIMHD NIH HHS U01 MD010579NINDS NIH HHS K23 NS100816NINDS NIH HHS R01 NS036695NINDS NIH HHS R01 NS093870NINDS NIH HHS R01 NS103924NINDS NIH HHS R24 NS092983NINDS NIH HHS U01 NS069763
6 · The paper itself

Abstract

BACKGROUND AND

objectivesAlthough blood pressure (BP) control is considered the most effective measure to prevent functional decline after intracerebral hemorrhage (ICH), fewer than half of survivors achieve treatment goals. We hypothesized that long-term (i.e., prehemorrhage) hypertension severity may be a crucial factor in explaining poor BP control after ICH. We investigated changes in hypertension severity after vs before ICH using latent class analysis (LCA) and identified patient characteristics predictive of individuals' BP trajectories.

methodsWe analyzed data for ICH survivors enrolled in a study conducted at Massachusetts General Hospital (MGH) from 2002 to 2019 in Boston, a high-resource setting with near-universal medical insurance coverage. We captured BP measurements in the 12 months preceding and following the acute ICH hospitalization. Using LCA, we identified patient groups (classes) based on changes in hypertension severity over time in an unbiased manner. We then created multinomial logistic regression models to identify patient factors associated with these classes.

resultsAmong 336 participants, the average age was 74.4 years, 166 (49%) were male, and 288 (86%) self-reported White race/ethnicity. LCA identified 3 patient classes, corresponding to minimal (n = 114, 34%), intermediate (n = 128, 38%), and substantial (n = 94, 28%) improvement in hypertension severity after vs before ICH. Survivors with undertreated (relative risk ratio [RRR] 0.05, 95% CI 0.01-0.23) or resistant (RRR 0.03, 95% CI 0.01-0.06) hypertension before ICH were less likely to experience substantial improvement afterwards. Residents of high-income neighborhoods were more likely to experience substantial improvement (RRR 1.14 per $10,000, 95% CI 1.02-1.28). Black, Hispanic, and Asian participants with uncontrolled hypertension before ICH were more likely to experience minimal improvement after hemorrhagic stroke (interaction DISCUSSION: Most ICH survivors do not display consistent improvement in hypertension severity after hemorrhagic stroke. BP control after ICH is profoundly influenced by patient characteristics predating the hemorrhage, chiefly prestroke hypertension severity and socioeconomic status. Neighborhood income was associated with hypertension severity after ICH in a high-resource setting with near-universal health care coverage. These findings likely contribute to previously documented racial/ethnic disparities in BP control and clinical outcomes following ICH.

Indexed as

HypertensionSocial Determinants of HealthAgedBlack or African AmericanCerebral HemorrhageHumansMaleRisk FactorsWhite People

Identifiers

PMID35131909
PMCPMC8967426
OpenAlexW4210834130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.